Session » (1088–1122) Immunological Complications of Medical Therapy Poster

Date: Monday, October 27, 2025

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2025

10:30AM-12:30PM: Abstract Number: 1122

A Retrospective Study of Adverse Cardiovascular Events in Patients Started on JAK Inhibitors at Two Major Health Systems in Northeast Ohio: Analysis of the 2019 JAK Inhibitors FDA Boxed Warning for Increased Risk of Serious Heart-Related Problems

10:30AM-12:30PM: Abstract Number: 1105

Association between pre-existing rheumatoid arthritis and immune-related adverse events in patients with cancer receiving immune checkpoint inhibitors

10:30AM-12:30PM: Abstract Number: 1100

Associations Between Pre-Existing Autoimmunity and CAR T Cell Therapy Toxicity for Cancer Treatment: A Nationwide Retrospective Cohort Study

10:30AM-12:30PM: Abstract Number: 1107

Baseline Data on Rheumatic Immune-related Adverse Events from the Largest Prospective Multicenter US Consortium

10:30AM-12:30PM: Abstract Number: 1108

Baseline Features, Immunosuppression, and Immune-Related Adverse Events in Patients with Pre-existing Rheumatic Disease and Cancer Requiring Immune Checkpoint Inhibitor Therapy

10:30AM-12:30PM: Abstract Number: 1112

Breaking Bones, Breaking Hearts: A FAERS Perspective on Osteoporosis Medications

10:30AM-12:30PM: Abstract Number: 1094

Changes in NK cells and TH cell phenotype in Rheumatoid Arthritis patients treated with janus kinase inhibitors: implications for adverse effects

10:30AM-12:30PM: Abstract Number: 1109

Characteristics of SARS-CoV-2 infected Patients with Rheumatic Diseases on Rituximab: A Subanalysis of the COVID-19 Vaccine Booster in Immunocompromised Rheumatic Diseases (COVBIRD) Study

10:30AM-12:30PM: Abstract Number: 1111

Checkpoint Inhibitor Induced Myocarditis with Myositis/Myasthenia Gravis Concurrence: An Observational Study

10:30AM-12:30PM: Abstract Number: 1102

Checkpoint Inhibitor Inflammatory Arthritis: Single Center Case Identification and Chart Validation.

10:30AM-12:30PM: Abstract Number: 1089

Comparing the immunosuppressant burden in immune checkpoint inhibitor mediated inflammatory arthritis versus polymyalgia rheumatica: results from a prospective multicenter registry

10:30AM-12:30PM: Abstract Number: 1101

Distinct Clinical Phenotypes of Immune Checkpoint Inhibitor–Associated Arthritis: Comparative Analysis of Inflammatory Arthritis, Polymyalgia Rheumatica-like, Activated Crystalline, and Activated Osteoarthritis

10:30AM-12:30PM: Abstract Number: 1115

Evaluation Of The Global Toxicity Burden In Patients Treated With Checkpoint Inhibitors Addressed For a Rheumatologic Toxicity And Its Impact On Oncological Outcomes

10:30AM-12:30PM: Abstract Number: 1106

Faster Ellipsoid Zone Loss in Hydroxychloroquine Retinopathy with Tapering versus Discontinuation: A Longitudinal Optical Coherence Tomography Study from a Single Center in Taiwan

10:30AM-12:30PM: Abstract Number: 1113

Immune checkpoint inhibitor–associated myocarditis: Incidence, risk factors, and clinical outcomes in a global real-world cohort

10:30AM-12:30PM: Abstract Number: 1104

Immune Checkpoint Inhibitors and Cardiovascular Risk in Patients with Rheumatoid Arthritis and Cancer

10:30AM-12:30PM: Abstract Number: 1096

Impact of IL-6 Receptor and JAK Inhibitors on Humoral Immunity in Inflammatory Rheumatic Diseases: An Ambispective Study.

10:30AM-12:30PM: Abstract Number: 1118

Increased Risk of Azathioprine-Induced Leukopenia in Patients with Systemic Lupus Erythematosus: A 10-Year Retrospective Cohort Study at a Quaternary Care Hospital in Thailand

10:30AM-12:30PM: Abstract Number: 1117

Inflammatory Arthritis after Hematopoietic Stem Cell Transplant: A Case Series and Literature Review

10:30AM-12:30PM: Abstract Number: 1121

Latent Class Analysis Identifies Distinct Phenotypes of Multisystem Immune-Related Adverse Events Predictive of Survival After Immune Checkpoint Inhibitors

10:30AM-12:30PM: Abstract Number: 1119

Microbial activation of cytotoxic CD8⁺ T cells promotes skin immune-related adverse events in patients treated with immune checkpoint inhibitors

10:30AM-12:30PM: Abstract Number: 1114

Multi-omics Integration Analysis of the Cross-scale Mechanism of MTX-induced T2DM Risk and the Precise Intervention Strategy of Leonurine

10:30AM-12:30PM: Abstract Number: 1097

Polymyalgia rheumatica and giant cell arteritis induced by immune checkpoint inhibitors: a systematic review and meta-analysis highlighting differences with the idiopathic forms

10:30AM-12:30PM: Abstract Number: 1092

Prior history of arthritis and PD-1 over PD-L1 blockade predispose to immune-related adverse events in cancer patients treated with immune checkpoint inhibitors

10:30AM-12:30PM: Abstract Number: 1090

Quantitative Immunoglobulin Screening Prior to Rituximab Initiation: A Retrospective Cohort Study

10:30AM-12:30PM: Abstract Number: 1093

Rituximab Associated Risk for Progressive Multifocal Leukoencephalopathy Among Patients with Systemic Lupus Erythematosus: A Retrospective Cohort Study

10:30AM-12:30PM: Abstract Number: 1099

Safety and Effectiveness of Hydroxychloroquine in the Treatment of Rheumatic Immune-Related Adverse Events

10:30AM-12:30PM: Abstract Number: 1091

Safety Profile of ICIs in Patients with Rheumatoid Arthritis: Results from a Propensity Score-Matched Cohort Study

10:30AM-12:30PM: Abstract Number: 1116

Second-line Therapy for Immune-checkpoint Inhibitor-induced Pneumonitis

10:30AM-12:30PM: Abstract Number: 1120

Synergistic Effects of IL-17F and IL-17A on Neutrophil Chemotaxis: Increased Risk of Candidiasis with Dual Blockade of IL-17A and IL17-F

10:30AM-12:30PM: Abstract Number: 1098

Tolerability of Apremilast: Gastrointestinal Side Effects Dominate While Cardiac Safety Remains Reassuring

10:30AM-12:30PM: Abstract Number: 1095

Tolerance of non-TNF α treatments in patient with an inflammatory rheumatic (IRD) and autoimmune demyelinating diseases: French retrospective cases series

10:30AM-12:30PM: Abstract Number: 1110

Tumor outcomes and arthritis flares in patients with pre-existing rheumatoid arthritis receiving immune checkpoint inhibitor therapy

10:30AM-12:30PM: Abstract Number: 1088

Unsupervised characterization of immune checkpoint inhibitor induced inflammatory arthritis using cluster and latent class analysis: result from a multicenter prospective registry

10:30AM-12:30PM: Abstract Number: 1103

Validation of the Health Assessment Questionnaire Disability Index in Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].